BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes

DOI: 10.1200/jco.2002.05.121
Journal of Clinical Oncology, 2002, 20, 2701-12.

#	Paper	IF	Citations
460	Screening for lung cancer. *Journal of Clinical Oncology*, **2002**, 20, 3931; author reply 3931-4	2.2	0
459	Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. **2002**, 39, 611-4		76
458	Chronomodulated chemotherapy in advanced colorectal carcinoma. *Journal of Clinical Oncology*, **2002**, 20, 3937-8; author reply 3938-9	2.2	2
457	Nonovarian pelvic cancers in BRCA1/2 mutation carriers and the BRCAPRO statistical model. *Journal of Clinical Oncology*, **2002**, 20, 3936; author reply 3936-7	2.2	3
456	p53 and MDM2 in germ cell cancer treatment response. *Journal of Clinical Oncology*, **2002**, 20, 3928; author reply 3928-9	2.2	10
455	Ethical issues surrounding the conduct of off-shore clinical research. *Journal of Clinical Oncology*, **2002**, 20, 3934; author reply 3934-6	2.2	
454	Adjuvant radiation for stage IIb soft tissue sarcoma of the extremity. *Journal of Clinical Oncology*, **2002**, 20, 3929-30; author reply 3930	2.2	2
453	Nutrition and survival after the diagnosis of breast cancer: a review of the evidence. *Journal of Clinical Oncology*, **2002**, 20, 3302-16	2.2	319
452	ERRATUM. *Journal of Clinical Oncology*, **2002**, 20, 3939-3939	2.2	
451	Colostomies may influence patient quality of life more than poor sphincter function. *Journal of Clinical Oncology*, **2002**, 20, 3930-1; author reply 3931	2.2	4
450	Breast cancer risk communication: challenges and future research directions: workshop report (United States). **2003**, 14, 235-9		5
449	Subjective and Objective Risks of Carrying a BRCA1/2 Mutation in Individuals of Ashkenazi Jewish Descent. **2003**, 12, 351-71		12
448	Available models for breast cancer risk assessment: how accurate are they?. **2003**, 197, 1029-35		4
447	Evidence-based management options for women at increased breast/ovarian cancer risk. **2003**, 14, 9-19		37
446	Hereditary breast-ovarian cancer at the bedside: role of the medical oncologist. *Journal of Clinical Oncology*, **2003**, 21, 740-53	2.2	51
445	A clinical, histopathological, and genetic study of Avellino corneal dystrophy in British families. **2003**, 40, 596-596		78
444	Clinical practice. Mammographic screening for breast cancer. **2003**, 348, 1672-80		256

443	Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. **2003**, 138, 1323-8; discussion 1329		137
442	Application of breast cancer risk prediction models in clinical practice. *Journal of Clinical Oncology*, **2003**, 21, 593-601	2.2	150
441	Carrier risk status changes resulting from mutation testing in hereditary non-polyposis colorectal cancer and hereditary breast-ovarian cancer. **2003**, 40, 591-6		18
440	Breast cancer risk assessment: a guide for clinicians using the NCCN Breast Cancer Risk Reduction Guidelines. **2003**, 1, 297-301		2
439	The advanced practice nursing role in a high-risk breast cancer clinic. **2003**, 30, 115-22		19
438	The Importance of Family History Evaluation in a Breast Surgery or Oncology Practice. **2003**, 20, 83-91		
437	Cancer genetics in primary care. **2003**, 133, 3767S-3772S		6
436	BayesMendel: an R environment for Mendelian risk prediction. **2004**, 3, Article21		56
435	Genetic alterations in hereditary breast cancer. **2004**, 15 Suppl 1, I7-I13		39
434	Risk estimation for healthy women from breast cancer families: new insights and new strategies. *Cancer Epidemiology Biomarkers and Prevention*, **2004**, 13, 87-93	4	39
433	Hereditary cancer: guidelines in clinical practice. Breast and ovarian cancer genetics. **2004**, 15 Suppl 4, iv133-8		18
432	Imaging of the ovary. **2004**, 3, 617-27		47
431	A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. **2004**, 41, 474-80		189
430	Effect of a computer-based decision aid on knowledge, perceptions, and intentions about genetic testing for breast cancer susceptibility: a randomized controlled trial. **2004**, 292, 442-52		229
429	Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations. **2004**, 41, 278-85		50
428	Risk modeling in breast cancer. **2004**, 10 Suppl 1, S10-2		11
427	Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations. **2004**, 12, 899-906		46
426	The BOADICEA model of genetic susceptibility to breast and ovarian cancer. **2004**, 91, 1580-90		353

425	Genetic testing for breast and ovarian cancer susceptibility: a family experience. **2004**, 49, 210-9		15
424	Analysis of the time interval between diagnoses in women with double primary breast and ovarian or primary peritoneal cancers. **2004**, 94, 796-802		10
423	Malignant breast disease and risk assessment. **2004**, 54, S40-S51		
422	Frequency of the ATM IVS10-6T-->G variant in Australian multiple-case breast cancer families. **2004**, 6, R401-7		12
421	Cancer genetics in primary care. **2004**, 31, 649-83, xi		6
420	Current comprehensive assessment and management of women at increased risk for breast cancer. **2004**, 187, 349-62		36
419	Common hereditary cancer syndromes. **2004**, 20, 164-77		4
418	Recent developments in ovarian cancer genetics. **2004**, 16, 79-85		4
417	Use of an educational computer program before genetic counseling for breast cancer susceptibility: effects on duration and content of counseling sessions. **2005**, 7, 221-9		82
416	Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. **2005**, 143, 362-79		260
415	Impact of the Cancer Risk Intake System on patient-clinician discussions of tamoxifen, genetic counseling, and colonoscopy. **2005**, 20, 360-5		23
414	Risk assessment: controversies and management of moderate- to high-risk individuals. **2005**, 11 Suppl 1, S11-9		8
413	BRCA1 mutations and polymorphisms in a hospital-based consecutive series of breast cancer patients from Apulia, Italy. **2005**, 578, 395-405		44
412	Evaluation of hereditary risk in a mammography population. **2005**, 6, 38-44		21
411	Determining joint carrier probabilities of cancer-causing genes using Markov chain Monte Carlo methods. *Genetic Epidemiology*, **2005**, 29, 141-54	2.6	2
410	Linkage of a pedigree drawing program and database to a program for determining BRCA mutation carrier probability. **2005**, 4, 313-6		5
409	. **2005**,		1
408	Information and involvement preferences of women in their 40s before their first screening mammogram. **2005**, 165, 1370-4		18

407	Genetic counselling in breast and colorectal cancer. **2005**, 16 Suppl 2, ii163-9		
406	Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. **2005**, 97, 1382-4		70
405	Personalized diagnostic and therapeutic strategies in oncology. **2005**, 2, 97-110		1
404	Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. **2005**, 293, 1729-36		301
403	Allele imbalance, or loss of heterozygosity, in normal breast epithelium of sporadic breast cancer cases and BRCA1 gene mutation carriers is increased compared with reduction mammoplasty tissues. *Journal of Clinical Oncology*, **2005**, 23, 8613-9	2.2	35
402	Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. **2005**, 294, 1925-33		189
401	Cancer risk prediction models: a workshop on development, evaluation, and application. **2005**, 97, 715-23		200
400	Patients with an unclassified genetic variant in the BRCA1 or BRCA2 genes show different clinical features from those with a mutation. *Journal of Clinical Oncology*, **2005**, 23, 2185-90	2.2	18
399	Strengths and limitations of breast cancer risk assessment. **2005**, 32, 605-16		4
398	Article on mitoxantrone-induced extravasation raised useful questions. **2005**, 32, 719-20		
397	Diagnostic g□□ique du cancer du sein et de l□ovaire h□□itaire. **2005**, 15, 76-92		
396	Population-Calibrated Gene Characterization: Estimating Age at Onset Distributions Associated With Cancer Genes. **2005**, 100, 399-409		11
395	Genetic Counseling for Patients with Breast Cancer and Their Families. **2005**, 319-330		
394	BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. **2006**, 8, R3		64
393	What can be learnt from models of incidence rates?. **2006**, 8, 208		18
392	Disparities in genetic testing: thinking outside the BRCA box. *Journal of Clinical Oncology*, **2006**, 24, 2197-203	2.2	126
391	Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent. **2006**, 70, 320-9		24
390	Numerous high-risk epithelial lesions in familial breast cancer. **2006**, 42, 2492-8		25

389	Carcinogen-induced DNA double strand break repair in sporadic breast cancer. **2006**, 135, 120-8		12
388	Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing. **2006**, 30, 1357-66		36
387	Prospective screening study of 0.5 Tesla dedicated magnetic resonance imaging for the detection of breast cancer in young, high-risk women. **2006**, 6, 10		5
386	Breast cancer risk assessment and prevention: a framework for shared decision-making consultations. **2006**, 12, 103-13		70
385	Improving the accuracy of BRCA1/2 mutation prediction: validation of the novel country-customized IC software. **2006**, 14, 49-54		15
384	BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers. **2006**, 57, 1-23		49
383	BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families. **2006**, 5, 379-87		28
382	Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families. *Breast Cancer Research and Treatment*, **2006**, 100, 83-91	4.4	21
381	Molecular screening for breast cancer prevention, early detection, and treatment planning: combining biomarkers from DNA, RNA, and protein. **2006**, 8, 484-91		8
380	Best surgical prophylaxis--risk-reducing mastectomy for women at high personal risk of breast cancer. **2006**, 15 Suppl 2, S21-5		3
379	BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models. **2006**, 17 Suppl 7, vii34-40		29
378	Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. **2006**, 12, 3661-97		235
377	Mammographic density correlation with Gail model breast cancer risk estimates and component risk factors. *Cancer Epidemiology Biomarkers and Prevention*, **2006**, 15, 1324-30	4	29
376	Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. **2006**, 295, 891-4		505
375	Assessing BRCA carrier probabilities in extended families. *Journal of Clinical Oncology*, **2006**, 24, 354-60	2.2	85
374	Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives. **2006**, 24, 484-91		16
373	In Reply. *Journal of Clinical Oncology*, **2006**, 24, 3313-3314	2.2	4
372	Risk prediction models for familial breast cancer. **2006**, 2, 257-74		72

371	Evaluation of models to predict BRCA germline mutations. **2006**, 95, 914-20		53
370	Optimal selection for BRCA1 and BRCA2 mutation testing using a combination of 'easy to apply' probability models. **2006**, 95, 757-62		11
369	Optimal selection of individuals for BRCA mutation testing: a comparison of available methods. *Journal of Clinical Oncology*, **2006**, 24, 707-15	2.2	100
368	Analysis of PALB2/FANCN-associated breast cancer families. **2007**, 104, 6788-93		173
367	Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. **2007**, 244, 381-8		299
366	In Reply. *Journal of Clinical Oncology*, **2007**, 25, 2634-2635	2.2	
365	BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model. *Journal of Clinical Oncology*, **2007**, 25, 4635-41	2.2	58
364	Does the search for large genomic rearrangements impact BRCAPRO carrier prediction?. *Journal of Clinical Oncology*, **2007**, 25, 2632-4; author reply 2634-5	2.2	5
363	Einführung in die Genetische Epidemiologie. **2007**,		
362	High prevalence of BRCA1 deletions in BRCAPRO-positive patients with high carrier probability. **2007**, 18 Suppl 6, vi86-92		16
361	Genetic testing in diverse populations: are researchers doing enough to get out the correct message?. **2007**, 298, 2910-1		18
360	Hereditary Breast Cancer. **2007**,		
359	Validity of models for predicting BRCA1 and BRCA2 mutations. **2007**, 147, 441-50		87
358	Assessing breast cancer risk and BRCA1/2 carrier probability. **2006**, 27, 5-20		17
357	Evaluation of mathematical models for breast cancer risk assessment in routine clinical use. **2007**, 16, 216-24		25
356	Risk and risk assessment for breast cancer: molecular and clinical aspects. **2007**, 57, 56-60		14
355	Breast cancer risk-assessment models. **2007**, 9, 213		90
354	Beyond standard mammographic screening: mammography at age extremes, ultrasound, and MR imaging. **2007**, 45, 895-906, vii		24

353	Molecular Pathology in Clinical Practice. **2007**,	3
352	Management of the BRCA mutation carrier or high-risk patient. **2007**, 34, 15-27; abstract v	6
351	Clinical practice. Management of an inherited predisposition to breast cancer. **2007**, 357, 154-62	194
350	A novel cognitive interpretation of breast cancer thermography with complementary learning fuzzy neural memory structure. **2007**, 33, 652-666	82
349	Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. **2007**, 7, 937-48	339
348	Assessing intraepithelial neoplasia and drug safety in cancer-preventive drug development. **2007**, 7, 508-18	20
347	Identification of novel BRCA large genomic rearrangements in Singapore Asian breast and ovarian patients with cancer. **2007**, 71, 331-42	43
346	Breast cancer risk assessment and management in primary care: provider attitudes, practices, and barriers. **2007**, 31, 375-83	75
345	Validation study of the LAMBDA model for predicting the BRCA1 or BRCA2 mutation carrier status of North American Ashkenazi Jewish women. **2007**, 72, 87-97	10
344	Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of LAMBDA, BRCAPRO, Myriad II, and modified Couch models. **2007**, 6, 473-82	16
343	Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors. **2007**, 16, 241-60	155
342	Estimation and interpretation of models of absolute risk from epidemiologic data, including family-based studies. **2008**, 14, 18-36	9
341	Family history of pancreatic cancer in a high-risk cancer clinic: implications for risk assessment. **2008** , 17, 365-72	5
340	Selecting a BRCA risk assessment model for use in a familial cancer clinic. **2008**, 9, 116	36
339	The American Cancer Society guidelines for breast screening with magnetic resonance imaging: an argument for genetic testing. **2008**, 113, 3116-20	21
338	Genetic evidence and integration of various data sources for classifying uncertain variants into a single model. **2008**, 29, 1265-72	145
337	The clinical content of preconception care: preconception care for special populations. **2008**, 199, S384-8	16
336	Methods of Cancer Diagnosis, Therapy and Prognosis. **2008**,	13

335	Advances in Breast Cancer Management, Second Edition. **2008**,		1
334	Evaluation of unclassified variants in the breast cancer susceptibility genes BRCA1 and BRCA2 using five methods: results from a population-based study of young breast cancer patients. **2008**, 10, R19		17
333	Concise handbook of familial cancer susceptibility syndromes - second edition. **2008**, 1-93		136
332	Breast Cancer. **2008**,		3
331	Performance of BRCA1/2 mutation prediction models in Asian Americans. *Journal of Clinical Oncology*, **2008**, 26, 4752-8	2.2	52
330	BRCA1 and BRCA2 risk perceptions among African American women at increased risk for hereditary breast-ovarian cancer. **2008**, 11, 193-200		2
329	Increased uptake of BRCA1/2 genetic testing among African American women with a recent diagnosis of breast cancer. *Journal of Clinical Oncology*, **2008**, 26, 32-6	2.2	49
328	Hereditary Gynecologic Cancer. **2008**,		2
327	Early Detection of Cancer. **2008**, 335-347		0
326	Novel breast tissue feature strongly associated with risk of breast cancer. *Journal of Clinical Oncology*, **2009**, 27, 5893-8	2.2	37
325	Interpreting trial results in light of conflicting evidence: a Bayesian analysis of adjuvant chemotherapy for non-small-cell lung cancer. *Journal of Clinical Oncology*, **2009**, 27, 2245-52	2.2	16
324	Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling. **2009**, 20, 874-8		20
323	Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population. **2009**, 11, 783-9		77
322	Tailored supplemental screening for breast cancer: what now and what next?. **2009**, 192, 390-9		124
321	A screening and prevention programme serving an ethnically diverse population of women at high risk of developing breast and/or ovarian cancer. **2009**, 3,		2
320	Hormone Receptors in Breast Cancer. **2009**,		
319	Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 1084-91	4	53
318	Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States. *Journal of Clinical Oncology*, **2009**, 27, 1184-90	2.2	40

317	cDNA analysis demonstrates that the BRCA2 intronic variant IVS4-12del5 is a deleterious mutation. **2009**, 663, 84-9		8
316	Accuracy of the BRCAPRO model among women with bilateral breast cancer. **2009**, 115, 725-30		15
315	Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients. *Breast Cancer Research and Treatment*, **2009**, 116, 563-70	4.4	17
314	Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy. *Breast Cancer Research and Treatment*, **2009**, 117, 497-504	4.4	27
313	Models for predicting BRCA1 and BRCA2 mutations in Han Chinese familial breast and/or ovarian cancer patients. *Breast Cancer Research and Treatment*, **2009**, 113, 467-77	4.4	9
312	Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations. **2009**, 8, 153-8		29
311	Experiences and decisions that motivate women at increased risk of breast cancer to participate in an experimental screening program. **2009**, 18, 160-72		10
310	The effectiveness of family history questionnaires in cancer genetic counseling. **2009**, 18, 366-78		21
309	Identification and management of women at high risk for hereditary breast/ovarian cancer syndrome. **2009**, 15, 155-62		49
308	Genetic counseling and the advanced practice oncology nursing role in a hereditary cancer prevention clinic: hereditary breast cancer focus (part II). **2009**, 15 Suppl 1, S11-9		1
307	Beyond Standard Mammographic Screening: Mammography at Age Extremes, Ultrasound, and MR Imaging. **2009**, 4, 135-147		1
306	Subjective versus objective risk in genetic counseling for hereditary breast and/or ovarian cancers. **2009**, 28, 157		25
305	A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history. **2009**, 11, R8		40
304	Breast Cancer in the Post-Genomic Era. **2009**,		3
303	Eleven years disease-free: role of chemotherapy in metastatic BRCA2-related breast cancer. **2009**, 6, 488-92		18
302	Women at high risk for breast cancer--what the primary care provider needs to know. **2009**, 22, 43-50		20
301	Cancer genetic counseling in rural North Carolina oncology clinics: program establishment and patient characteristics. **2009**, 6, 70-77		3
300	Approaches to applying breast cancer risk prediction models in clinical practice. **2009**, 6, 373-382		6

299	Genetic counseling and the advanced practice oncology nursing role in a hereditary cancer prevention clinic: hereditary breast cancer focus (part I). **2009**, 15 Suppl 1, S2-10		5
298	Ovarian cancer. **2009**, 374, 1371-82		477
297	Screening and prevention of breast cancer in primary care. **2009**, 36, 533-58		19
296	Moving toward personalized medicine: treatment-focused genetic testing of women newly diagnosed with ovarian cancer. **2010**, 20, 704-16		22
295	Breast cancer risk in women who fulfill high-risk criteria: at what age should surveillance start?. *Breast Cancer Research and Treatment*, **2010**, 121, 133-41	4.4	14
294	Maternal and paternal lineage double heterozygosity alteration in familial breast cancer: a first case report. *Breast Cancer Research and Treatment*, **2010**, 124, 875-8	4.4	9
293	A PALB2 germline mutation associated with hereditary breast cancer in Italy. **2010**, 9, 181-5		37
292	Efficiency of BRCAPRO and Myriad II mutation probability thresholds versus cancer history criteria alone for BRCA1/2 mutation detection. **2010**, 9, 193-201		10
291	Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study. **2010**, 9, 495-502		39
290	The contribution of breast cancer pathology to statistical models to predict mutation risk in BRCA carriers. **2010**, 9, 545-53		18
289	Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. **2010**, 60, 99-119		321
288	BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer. **2010**, 49, 1143-51		20
287	The BRCAPRO 5.0 model is a useful tool in genetic counseling and clinical management of male breast cancer cases. **2010**, 18, 856-8		13
286	Multimodality breast cancer screening in women with a familial or genetic predisposition. **2010**, 17, 28-36		34
285	Lessons learned from genetic testing. **2010**, 304, 1011-2		9
284	Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. *Journal of Clinical Oncology*, **2010**, 28, 1450-7	2.2	346
283	Assessing women at high risk of breast cancer: a review of risk assessment models. **2010**, 102, 680-91		334
282	Biomedical Informatics for Cancer Research. **2010**,		8

281	Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. **2010**, 107, 12629-33		372
280	Clinical application of breast cancer risk assessment models. **2010**, 6, 355-65		10
279	Prevention of breast cancer (part I): epidemiology, risk factors, and risk assessment tools. **2010**, 28, 743-50		52
278	BRCA1 and BRCA2 genetic test in high risk patients and families: counselling and management. **2010**, 24, 1661-7		8
277	Reasons women at elevated risk of breast cancer refuse breast MR imaging screening: ACRIN 6666. **2010**, 254, 79-87		122
276	Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. *Journal of Clinical Oncology*, **2010**, 28, 3570-6	2.2	290
275	Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. **2010**, 7, 18-27		525
274	The use of breast imaging to screen women at high risk for cancer. **2010**, 48, 859-78		62
273	The role of BRCA mutation testing in determining breast cancer therapy. **2010**, 7, 708-17		74
272	Recent developments in the ability to predict and modify breast cancer risk. **2010**, 63, 1581-7		9
271	Development of a scoring system to screen for BRCA1/2 mutations. **2010**, 653, 237-47		6
270	Colorectal Cancer. **2010**, 457-476		
269	Femmes haut risque de cancer mammaire´: vers des unit et r eaux de surveillance. **2011**, 21, 3-11		
268	Differences between women who pursued genetic testing for hereditary breast and ovarian cancer and their at-risk relatives who did not. **2011**, 38, 572-81		16
267	Inherited Cancer Syndromes. **2011**,		1
266	Magnetic resonance imaging and breast ultrasonography as an adjunct to mammographic screening in high-risk patients. **2011**, 32, 266-72		27
265	Apparently "BRCA-related" breast and ovarian cancer patient with germline TP53 mutation. **2011**, 17, 409-15		4
264	Cancer screening in the United States, 2011: A review of current American Cancer Society guidelines and issues in cancer screening. **2011**, 61, 8-30		190

263	Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine. **2011**, 61, 327-59		128
262	The use of family history questionnaires: an examination of genetic risk estimates and genetic testing eligibility in the non-responder population. **2011**, 20, 355-64		6
261	Mutations and polymorphic BRCA variants transmission in breast cancer familial members. *Breast Cancer Research and Treatment*, **2011**, 125, 651-7	4.4	18
260	Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Greece. **2011**, 9, 10		19
259	Atypical presentation of Lynch Syndrome: a case report. **2011**, 9, P10		78
258	Personalized estimates of breast cancer risk in clinical practice and public health. **2011**, 30, 1090-104		59
257	Breast Cancer Risk - Genes, Environment and Clinics. **2011**, 71, 1056-1066		45
256	Interest in genetic testing for modest changes in breast cancer risk: implications for SNP testing. **2011**, 14, 178-89		44
255	Telemedicine vs in-person cancer genetic counseling: measuring satisfaction and conducting economic analysis. **2011**, 43		3
254	Denosumab as Bone Modifying Therapy in Solid Tumors. **2011**, 3, 107-113		
253	Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. *Journal of Clinical Oncology*, **2011**, 29, 4373-80	2.2	87
252	Computational modeling and multilevel cancer control interventions. **2012**, 2012, 56-66		16
251	Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles. **2012**, 8, e1002894		144
250	Evaluating breast cancer risk with genome-wide association studies: is this approach patient ready?. *Journal of Clinical Oncology*, **2012**, 30, 4288-9	2.2	
249	Efficient identification and referral of low-income women at high risk for hereditary breast cancer: a practice-based approach. **2012**, 15, 172-80		22
248	A role for common genomic variants in the assessment of familial breast cancer. *Journal of Clinical Oncology*, **2012**, 30, 4330-6	2.2	60
247	Genetic testing by cancer site: breast. **2012**, 18, 310-9		17
246	BRCA1 and BRCA2 Molecular Testing in Women with Different Risk of Hereditary Breast Cancer: ost/Effectiveness and Psychological Implications. **2012**, 8, 12-16		4

245	Differences in US healthcare coverage policies in BRCA testing and potential implications. **2012**, 9, 5-8		3
244	Celebrating 70: An Interview with Don Berry. **2012**, 27,		4
243	Genetic determinants of breast cancer risk: a review of current literature and issues pertaining to clinical application. **2012**, 18, 436-42		32
242	Accuracy of BRCA1/2 mutation prediction models in Korean breast cancer patients. *Breast Cancer Research and Treatment*, **2012**, 134, 1189-97	4.4	15
241	Outcomes of a systems-level intervention offering breast cancer risk assessments to low-income underserved women. **2012**, 11, 493-502		18
240	Portuguese c.156_157insAlu BRCA2 founder mutation: gastrointestinal and tongue neoplasias may be part of the phenotype. **2012**, 11, 657-60		9
239	Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes. **2012**, 91, 97-108		173
238	Identification of the prevalent BRCA1 and BRCA2 mutations in the female population of Puerto Rico. **2012**, 205, 242-8		27
237	Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing. **2012**, 43, 1932-9		5
236	Mathematical modeling of the immune system recognition to mammary carcinoma antigen. **2012**, 13 Suppl 17, S21		34
235	Parallel factor analysis of ovarian autofluorescence as a cancer diagnostic. **2012**, 44, 282-95		13
234	Accuracy of BRCA1/2 mutation prediction models for different ethnicities and genders: experience in a southern Chinese cohort. **2012**, 36, 702-13		17
233	Family history and risk of breast cancer: nurses' health study. *Breast Cancer Research and Treatment* , **2012**, 133, 1097-104	4.4	72
232	Cancer screening in the United States, 2012: A review of current American Cancer Society guidelines and current issues in cancer screening. **2012**, 62, 129-42		107
231	Beyond mammography: new frontiers in breast cancer screening. **2013**, 126, 472-9		126
230	Genetic Evaluation for Common Diseases of Adulthood. **2013**, 1-13		
229	Retrospective analysis of clinicopathological characteristics and family history data of early-onset breast cancer: a single-institutional study of Hungarian patients. **2013**, 19, 723-9		5
228	Communicating risk of hereditary breast and ovarian cancer with an interactive decision support tool. **2013**, 92, 188-96		17

227	Breast magnetic resonance imaging for screening high-risk women. **2013**, 21, 509-17		16
226	Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. **2013**, 20, 3254-8		145
225	The incidence of PALB2 c.3113G>A in women with a strong family history of breast and ovarian cancer attending familial cancer centres in Australia. **2013**, 12, 587-95		9
224	Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. **2013**, 63, 88-105		194
223	Prediction of BRCA1 germ-line mutation status in patients with breast cancer using histoprognosis grade, MS110, Lys27H3, vimentin, and KI67. **2013**, 80, 219-27		10
222	Practical aspects of genetic counseling in breast cancer: lights and shadows. **2013**, 22, 375-82		26
221	Hereditary cancer risk assessment: essential tools for a better approach. **2013**, 11, 16		5
220	Clinical decision support for genetically guided personalized medicine: a systematic review. **2013**, 20, 388-400		79
219	Breast Cancer Risk - From Genetics to Molecular Understanding of Pathogenesis. **2013**, 73, 1228-1235		31
218	Which risk model to use? Clinical implications of the ACS MRI screening guidelines. *Cancer Epidemiology Biomarkers and Prevention*, **2013**, 22, 146-9	4	46
217	Establishing a program for individuals at high risk for breast cancer. **2013**, 4, 433-46		11
216	Pathogenesis, prevention, diagnosis and treatment of breast cancer. **2014**, 5, 283-98		130
215	Nucleic Acid-Based Diagnostics in Gynecological Malignancies. **2014**, 155-184		
214	. **2014**,		1
213	Implementing a screening tool for identifying patients at risk for hereditary breast and ovarian cancer: a statewide initiative. **2014**, 21, 3342-7		19
212	Misreported family histories and underestimation of risk. *Journal of Clinical Oncology*, **2014**, 32, 3682-3	2.2	3
211	Germline DNA variations in breast cancer predisposition and prognosis: a systematic review of the literature. **2014**, 144, 77-91		27
210	A review of clinical aspects of breast cancer. **2014**, 26, 4-15		80

209	Prophylactic bilateral mastectomy and contralateral prophylactic mastectomy. **2014**, 23, 423-30		8
208	Development of a personalized decision aid for breast cancer risk reduction and management. **2014**, 14, 4		28
207	Cancer screening in the United States, 2014: a review of current American Cancer Society guidelines and current issues in cancer screening. **2014**, 64, 30-51		140
206	Reclassification of predictions for uncovering subgroup specific improvement. **2014**, 33, 1914-27		4
205	Breast Cancer. **2014**,		3
204	Mathematical modeling for novel cancer drug discovery and development. **2014**, 9, 1133-50		17
203	Implementing family health history risk stratification in primary care: impact of guideline criteria on populations and resource demand. **2014**, 166C, 24-33		33
202	Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer. *Journal of Clinical Oncology*, **2014**, 32, 618-26	2.2	174
201	American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. *Journal of Clinical Oncology*, **2014**, 32, 833-40	2.2	164
200	The additional cancer yield of clinical breast examination in screening of women at hereditary increased risk of breast cancer: a systematic review. *Breast Cancer Research and Treatment*, **2014**, 147, 15-23	4.4	7
199	BRCA1/2 germline mutations and their clinical importance in Turkish breast cancer patients. **2014**, 32, 375-87		18
198	Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. **2014**, 160, 255-66		171
197	Optimal delivery of male breast cancer follow-up care: improving outcomes. **2015**, 7, 371-9		6
196	Cancer Visibility among Iranian Familial Networks: To What Extent Can We Rely on Family History Reports?. **2015**, 10, e0136038		8
195	Disparities in uptake of BRCA1/2 genetic testing in a randomized trial of telephone counseling. **2015**, 17, 467-75		68
194	Ductal Carcinoma In Situ and Microinvasive/Borderline Breast Cancer. **2015**,		1
193	Cancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screening. **2015**, 65, 30-54		271
192	Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer. **2015**, 21, 1574-82		101

191	Male Breast Cancer: A Study in Small Steps. **2015**, 20, 584-5		2
190	Does a High-Risk Recommendation in Mammography Reports Increase Attendance at a Breast Cancer Risk Assessment Clinic?. **2015**, 12, 923-9		8
189	Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling. **2015**, 24, 33-9		23
188	Large genomic rearrangements in the familial breast and ovarian cancer gene BRCA1 are associated with an increased frequency of high risk features. **2015**, 14, 287-95		17
187	To reflex or not: additional BRCA1/2 testing in Ashkenazi Jewish individuals without founder mutations. **2015**, 24, 285-93		7
186	Randomized Trial of Telegenetics vs. In-Person Cancer Genetic Counseling: Cost, Patient Satisfaction and Attendance. **2015**, 24, 961-70		106
185	Clinical decision support systems for improving diagnostic accuracy and achieving precision medicine. **2015**, 5, 4		175
184	BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing. **2015**, 20, 593-7		9
183	Breast cancer prevention across the cancer care continuum. **2015**, 31, 89-99		6
182	Genetic risk assessment for breast and gynecological malignancies. **2015**, 27, 1-5		3
181	Certified Genetic Counselors: A Crucial Clinical Resource in the Management of Patients with Suspected Hereditary Cancer Syndromes. **2015**, 24, 653-66		5
180	The Genetics of Breast Cancer: What the Surgical Oncologist Needs to Know. **2015**, 24, 705-32		3
179	Prevalence and differentiation of hereditary breast and ovarian cancers in Japan. *Breast Cancer*, **2015**, 22, 462-8	3.4	42
178	Hereditary cancer syndromes with high risk of endometrial and ovarian cancer: surgical options for personalized care. **2015**, 111, 118-24		19
177	Evaluation of BRCAPRO Risk Assessment Model in Patients with Ductal Carcinoma In situ Who Underwent Clinical BRCA Genetic Testing. **2016**, 7, 71		3
176	Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis. **2016**, 53, 591-9		40
175	Tumor characteristics and prognosis in familial breast cancer. **2016**, 16, 924		17
174	Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review. **2016**, 61, 137-45		46

173	Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer. **2016**, 35, 135		5
172	Cancer screening in the United States, 2016: A review of current American Cancer Society guidelines and current issues in cancer screening. **2016**, 66, 96-114		174
171	Breast Cancer Risk Assessment: Calculating Lifetime Risk Using the Tyrer-Cuzick Model. **2016**, 12, 581-592		16
170	A collaborative approach to cancer risk assessment services using genetic counselor extenders in a multi-system community hospital. *Breast Cancer Research and Treatment*, **2016**, 159, 527-34	4.4	19
169	Preventive health care. 1-16		
168	Genetics and cancer screening. 39-48		
167	Genetic anticipation in BRCA1/BRCA2 families after controlling for ascertainment bias and cohort effect. **2016**, 122, 1913-20		9
166	Patient and genetic counselor perceptions of in-person versus telephone genetic counseling for hereditary breast/ovarian cancer. **2016**, 15, 529-39		17
165	Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis. **2016**, 15, 497-506		5
164	Clinical utility of a Web-enabled risk-assessment and clinical decision support program. **2016**, 18, 1020-8		27
163	Patient Perceptions of Telephone vs. In-Person BRCA1/BRCA2 Genetic Counseling. **2016**, 25, 472-82		39
162	Patient and medical barriers preclude uptake of tamoxifen preventative therapy in women with a strong family history. **2017**, 32, 93-97		7
161	BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients. **2017**, 145, 137-141		10
160	Screening for breast cancer. **2017**, 44, 60-72		34
159	Molecular Diagnostics in Cancer. **2017**, 1-14		2
158	Breast Cancer Risk Assessment Models and High-Risk Screening. **2017**, 55, 457-474		17
157	Identification of large genomic rearrangement of BRCA1/2 in high risk patients in Korea. **2017**, 18, 38		7
156	Managing hereditary breast cancer risk in women with and without ovarian cancer. **2017**, 146, 205-214		11

155	Assessing Breast Cancer Risk Estimates Based on the Gail Model and Its Predictors in Qatari Women. **2017**, 8, 180-187		14
154	Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer. **2017**, 62, 379-387		0
153	Randomized Noninferiority Trial of Telephone vs In-Person Genetic Counseling for Hereditary Breast and Ovarian Cancer: A 12-Month Follow-Up. **2017**, 1, pkx002		11
152	The impact of hereditary cancer gene panels on clinical care and lessons learned. **2017**, 3,		27
151	Breast Cancer Before 40. **2017**, 177-202		0
150	Breast Cancer. **2017**, 1425-1434		
149	Six low-penetrance SNPs for the estimation of breast cancer heritability: A family-based study in Caucasian Italian patients. **2017**, 14, 4384-4390		2
148	The Preventive Intervention of Hereditary Breast Cancer. **2017**, 1026, 41-57		9
147	Time to Educate Physicians and Hospital Staff in Electronic Medical Records for Precision Medicine. **2017**, 217-232		
146	Simulation modeling for stratified breast cancer screening - a systematic review of cost and quality of life assumptions. **2017**, 17, 802		5
145	Breast Cancer Risk Model Requirements for Counseling, Prevention, and Screening. **2018**, 110, 994-1002		24
144	Randomized trial of proactive rapid genetic counseling versus usual care for newly diagnosed breast cancer patients. *Breast Cancer Research and Treatment*, **2018**, 170, 517-524	4.4	10
143	Comparison of Practice Guidelines, BRCAPRO, and Genetic Counselor Estimates to Identify Germline BRCA1 and BRCA2 Mutations in Pancreatic Cancer. **2018**, 27, 988-995		2
142	The impact of patient age on breast cancer risk prediction models. **2018**, 24, 592-598		4
141	Primary Prevention of Breast Cancer. **2018**, 219-236.e3		1
140	Informing Women and Their Physicians about Recommendations for Adjunct Breast MRI Screening: A Cohort Study. **2018**, 33, 489-495		5
139	Health and well-being management in the military: a systematic review of genetic studies. **2018**, 164, 302-308		4
138	Germline BRCA mutation in male carriers-ripe for precision oncology?. **2018**, 21, 48-56		11

137	Non-Coding Variants in and Genes: Potential Impact on Breast and Ovarian Cancer Predisposition. **2018**, 10,		9
136	2 History of Magnetic Resonance Imaging in Breast Cancer Screening. **2018**,		
135	Nipple-sparing mastectomy in women at high risk of developing breast cancer. **2018**, 7, 325-336		4
134	Review of non-clinical risk models to aid prevention of breast cancer. **2018**, 29, 967-986		8
133	Increased centrosome number in BRCA-related breast cancer specimens determined by immunofluorescence analysis. **2018**, 109, 2027-2035		7
132	Improving the diagnostic accuracy of a stratified screening strategy by identifying the optimal risk cutoff. **2019**, 30, 1145-1155		3
131	The role of BRCA1/2 in hereditary and familial breast and ovarian cancers. **2019**, 7, e879		19
130	[Inherited predisposition to breast cancer (2) : risks and surveillance]. **2019**, 35, 332-345		0
129	and Testing through Next Generation Sequencing in a Small Cohort of Italian Breast/Ovarian Cancer Patients: Novel Pathogenic and Unknown Clinical Significance Variants. **2019**, 20,		5
128	Screening and surgical prophylaxis for hereditary cancer syndromes with high risk of endometrial and ovarian cancer. **2019**, 120, 864-872		8
127	Breast Disease. **2019**,		
126	Multigene panel testing in unselected Israeli breast cancer cases: mutational spectrum and use of BRCA1/2 mutation prediction algorithms. *Breast Cancer Research and Treatment*, **2019**, 176, 165-170	4.4	4
125	A Comparative Study for Breast Cancer Prediction using Machine Learning and Feature Selection. **2019**,		10
124	Breast cancer risk assessment: Evaluation of screening tools for genetics referral. **2019**, 31, 562-572		
123	Risk Stratification for Screening Mammography: Benefits and Harms. **2019**, 212, 250-258		11
122	Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center. **2019**, 125, 690-697		8
121	Consumer and clinician perspectives on personalising breast cancer prevention information. **2019**, 43, 39-47		15
120	Germline mutations in cancer susceptibility genes in high grade serous ovarian cancer in Serbia. **2019**, 64, 281-290		9

119	Emergence of DSS efforts in genomics: Past contributions and challenges. **2019**, 116, 77-90		3
118	Bayesian Semiparametric Estimation of Cancer-specific Age-at-onset Penetrance with Application to Li-Fraumeni Syndrome. **2019**, 114, 541-552		3
117	Genetic Evaluation for Common, Chronic Disorders of Adulthood. **2019**, 265-282		
116	Predictors of risk-reducing surgery intentions following genetic counseling for hereditary breast and ovarian cancer. **2020**, 10, 337-346		5
115	Development of Malignancy-Risk Gene Signature Assay for Predicting Breast Cancer Risk. **2020**, 245, 153-162		1
114	Predictors of contralateral prophylactic mastectomy in genetically high risk newly diagnosed breast cancer patients. *Breast Cancer Research and Treatment*, **2020**, 180, 177-185	4.4	4
113	Screening and Early Detection. **2020**, 375-398.e7		1
112	Breast cancer prevention in high-risk women. **2020**, 65, 18-31		44
111	Current Approaches to Germline Cancer Genetic Testing. **2020**, 71, 85-102		7
110	At the intersection of precision medicine and population health: an implementation-effectiveness study of family health history based systematic risk assessment in primary care. **2020**, 20, 1015		6
109	An Update on Screening and Prevention for Breast and Gynecological Cancers in Average and High Risk Individuals. **2020**, 360, 489-510		
108	Predictors of genetic testing uptake in newly diagnosed breast cancer patients. **2020**, 122, 134-143		1
107	Genetic Testing and Screening Recommendations for Patients with Hereditary Breast Cancer. **2020**, 40, 913-936		5
106	Breast cancer risk, worry, and anxiety: Effect on patient perceptions of false-positive screening results. **2020**, 50, 104-112		5
105	F-test feature selection in Stacking ensemble model for breast cancer prediction. **2020**, 171, 1561-1570		11
104	Breast Cancer in Young Women. **2020**,		1
103	Evaluation of pathogenetic mutations in breast cancer predisposition genes in population-based studies conducted among Chinese women. *Breast Cancer Research and Treatment*, **2020**, 181, 465-473	4.4	7
102	Longitudinal study of breast cancer risk markers. **2021**, 27, 48-51		0

101	Early detection of prostate gland and breast cancer risk based on routine check-up data using survival analysis trees for left-truncated and right-censored data.	
100	Management of a Woman at Elevated Risk for Breast Cancer. **2021**, 107-136	
99	Acceptability of an mHealth breast cancer risk-reduction intervention promoting risk assessment, education, and discussion of risk in the primary care setting. **2021**, 7, 54	0
98	Present Options in the Prevention of Breast Cancer. **2021**, 117-127	
97	Assessing Risk of Breast Cancer: A Review of Risk Prediction Models. **2021**, 3, 144-155	7
96	Predicting the Future of Genetic Risk Profiling of Glaucoma: A Narrative Review. **2021**, 139, 224-231	2
95	Familial pancreatic cancer: who should be considered for genetic testing?. **2021**, 1	2
94	Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. **2021**, 146, 30-47	15
93	Endocrine prevention of breast cancer. **2021**, 530, 111284	1
92	Utilization of breast cancer risk prediction models by cancer genetic counselors in clinical practice predominantly in the United States. **2021**, 30, 1737-1747	1
91	Performance of the IBIS/Tyrer-Cuzick model of breast cancer risk by race and ethnicity in the Women's Health Initiative. **2021**, 127, 3742-3750	2
90	Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center. **2021**,	0
89	Role of Bioinformatics in cancer research and drug development. **2021**, 141-148	1
88	Inherited Breast Cancer. **2007**, 207-214	1
87	Recent advances in breast cancer genetics. **2008**, 141, 1-10	13
86	Biomedical Informatics for Cancer Research: Introduction. **2010**, 3-15	1
85	Genomic Cancer Risk Assessment. **2020**, 187-207	1
84	Colorectal Cancer. **2009**, 879-897	2

83	Primary Prevention of Breast Cancer. **2009**, 349-369		1
82	Breast Cancer Genetics. **2009**, 371-415		1
81	BRCA1/2 testing and cancer risk management in underserved women at a public hospital. **2012**, 9, 369-376		1
80	Positive impact of genetic counseling assistants on genetic counseling efficiency, patient volume, and cost in a cancer genetics clinic. **2020**, 22, 1348-1354		6
79	The genetic analysis of a founder Northern American population of European descent identifies FANCI as a candidate familial ovarian cancer risk gene.		1
78	Hypochondriacal delusion in an elderly man with good response to electroconvulsive therapy but complicated with febrile reaction. *Archives of Depression and Anxiety*, 038-041	1.6	1
77	Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk. **2019**, 10, 2855-2868		7
76	Genetic evaluation and testing for hereditary forms of cancer in the era of next-generation sequencing. **2016**, 13, 55-67		27
75	Supplemental Cancer Screening for Women With Dense Breasts: Guidance for Health Care Professionals. **2021**, 96, 2891-2904		1
74	Genetic Counseling for Hereditary Cancer Predisposition Testing. **2004**, 453-471		
73	Early Breast Cancer (Stage I and II): Tailored Radiotherapy for Very Young Women. **2006**, 279-289		
72	Familial Breast Cancer: Genetic Testing.		
71	Risk Prediction in Breast Cancer. **2007**, 19-33		
70	Models of Absolute Risk. **2008**, 259-274		
69	Genetic Risk Assessment for Hereditary Ovarian Cancer. **2008**, 219-235		
68	Strategies of hormonal prevention. **2009**, 147, 1-35		
67	A screening and prevention programme serving an ethnically diverse population of women at high risk of developing breast and/or ovarian cancer. **2009**, 3, 123		1
66	Inherited Breast Cancer. **2009**, 203-210		

65	Inherited Breast Cancer. **2009**, 41-48	
64	Identifying and Managing the High-Risk Patient. **2009**, 101-122	
63	The Genetics of Breast Cancer. **2009**, 39-54	
62	Identification and Management of Women at High Familial Risk for Breast Cancer. **2010**, 135-145	
61	Obtaining a History and Performing the Clinical Breast Examination. **2010**, 99-108	
60	Management of the Patient with a Genetic Predisposition for Breast Cancer. **2010**, 551-568	
59	Familial Cancer Risk Assessment Using BayesMendel. **2010**, 301-314	
58	Hereditary Breast Cancer Syndromes. **2011**, 51-104	
57	Ovarialkarzinom: alte Probleme und neue L□sungsans□tze. **2011**, 425-451	
56	Magnetic Resonance Imaging (MRI) in the Screening of High-Risk Patients and in the Detection and Diagnosis of Early Breast Cancer. **2011**, 45-55	1
55	Risk Assessment. **2014**, 3-30	
54	Breast Cancer. **2014**, 1-11	
53	Cancer Prevention, Screening, and Early Detection. **2014**, 322-359.e12	1
52	The genetics of breast cancer, risk-reducing surgery and prevention. **2014**, 127-145	
51	Breast Cancer Genetics and Risk Assessment. **2015**, 1-21	
50	DCIS and Hereditary Susceptibility for Breast Cancer. **2015**, 147-154	
49	Epidemiology, Risk Factors, and Prevention. **2016**, 57-87	1
48	Diagnostic Applications of Nuclear Medicine: Breast Cancer. **2016**, 1-25	

47	Hereditary Breast/Ovarian Cancer Syndrome: *BRCA1*. **2016**, 646-649		
46	Hereditary Breast/Ovarian Cancer Syndrome: *BRCA2*. **2016**, 650-653		
45	Inherited Breast Cancer. **2016**, 315-327		
44	Management of the Patient with a Genetic Predisposition for Breast Cancer. **2016**, 575-592		
43	Diagnostic Applications of Nuclear Medicine: Breast Cancer. **2017**, 613-637		
42	Risk Assessment for Breast Cancer. **2017**, 1-14		
41	Is genetic counseling for cancer predisposition always associated with distress? A pre-post intervention study to assess probands□pre-and post-counseling level of anxiety and satisfaction. *Archives of Depression and Anxiety*, 030-037	1.6	
40	Identification of the best index case significantly improves mutation detection rates in families with hereditary breast and ovarian cancer.		
39	Epidemiology, Risk Factors, and Prevention. **2019**, 39-61		
38	Assessment of the Gail Model in Estimating the Risk of Breast Cancer: Effect of Cancer Worry and Risk in Healthy Women. *Asian Pacific Journal of Cancer Prevention*, **2019**, 20, 1765-1771	1.7	0
37	Lifestyle Changes and Prevention: Unique Issues for Young Women. **2020**, 177-195		
36	High frequency of BRCA recurrent mutations in a consecutive series of unselected ovarian cancer patients. *Romanian Journal of Laboratory Medicine*, **2020**, 28, 257-266	0.3	1
35	The Cancer Spectrum Related to Hereditary and Familial Breast and Ovarian Cancers. **2009**, 143-155		
34	Genetic Screening and Counseling for High-Risk Populations. **2006**, 341-357		
33	Breast Cancer Risk in Women with Abnormal Cytology in Nipple Aspirate Fluid. **2008**, 203-216		
32	Thorax and Vasculature. **2008**, 663-861		
31	Risikoberechnungen in Familien. **2007**, 279-326		
30	A Systematic Review of Risk Factors and Risk Assessment Models for Breast Cancer. *Lecture Notes in Networks and Systems*, **2021**, 509-519	0.5	1

29	Assessing and managing breast cancer risk: clinical tools for advising patients. *MedGenMed: Medscape General Medicine*, **2004**, 6, 8		2
28	The construct of breast cancer risk perception: need for a better risk communication?. *Facts, Views & Vision in ObGyn*, **2009**, 1, 122-9	1.4	8
27	Magnetic Resonance Imaging as an Adjunct to Mammography for Breast Cancer Screening in Women at Less Than High Risk for Breast Cancer: A Health Technology Assessment. *Ontario Health Technology Assessment Series*, **2016**, 16, 1-30	3.1	3
26	Development and validation of a primary care-based family health history and decision support program (MeTree). *North Carolina Medical Journal*, **2013**, 74, 287-96	0.6	49
25	Novel Interactive Tool for Breast and Ovarian Cancer Risk Assessment (Bright Pink Assess Your Risk): Development and Usability Study.. *Journal of Medical Internet Research*, **2022**, 24, e29124	7.6	
24	Telephone versus in-person genetic counseling for hereditary cancer risk: Patient predictors of differential outcomes. *Journal of Telemedicine and Telecare*, **2021**, 1357633X211052220	6.8	0
23	Image retrieval-based parenchymal analysis for breast cancer risk assessment. *Medical Physics*, **2021** ,	4.4	
22	Familial Breast Cancer: Disease Related Gene Mutations and Screening Strategies for Chinese Population.. *Frontiers in Oncology*, **2021**, 11, 740227	5.3	
21	Predicting the Likelihood of Carrying a or Mutation in Asian Patients With Breast Cancer.. *Journal of Clinical Oncology*, **2022**, JCO2101647	2.2	1
20	Mutational spectrum of breast cancer susceptibility genes among women ascertained in a cancer risk clinic in Northeast Brazil.. *Breast Cancer Research and Treatment*, **2022**, 1	4.4	0
19	A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene. *Genome Medicine*, **2021**, 13, 186	14.4	2
18	Extraction of Electronic Health Record Data using Fast Healthcare Interoperability Resources for Automated Breast Cancer Risk Assessment.. **2021**, 2021, 843-852	0.7	
17	Diagnostic Applications of Nuclear Medicine: Breast Cancer. **2022**, 1-27		
16	Implications of BRCA1, BRCA2 Gene in Overall Development and Prognosis of Breast Cancer. **2022**, 87-112		
15	Statistical methods for Mendelian models with multiple genes and cancers.. *Genetic Epidemiology*, **2022**,	2.6	1
14	Significance of prostate/pancreatic/skin cancer family history for detecting BRCA2 pathogenic variant careers among patients with breast cancer. *Breast Cancer*,	3.4	0
13	BRCA1 and BRCA2 Mutations in a Study of African American Breast Cancer Patients. *Cancer Epidemiology Biomarkers and Prevention*, **2004**, 13, 1794-1799	4	16
12	Diagnostic Applications of Nuclear Medicine: Breast Cancer. **2022**, 715-741		0

11	Mutation Patterns in Portuguese Families with Hereditary Breast and Ovarian Cancer Syndrome. **2022**, 14, 4717	0
10	Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer. **2022**, 5, e2232787	0
9	Molecular Diagnostics in Cancer. 1-14	0
8	Genetics of Breast Cancer. **2022**,	1
7	Genes and cancer: Genetic counselling and clinical management. **2023**, 521-559.e6	0
6	Racial and ethnic variation in BRCA1 and BRCA2 genetic test results among individuals referred for genetic counseling at a large urban comprehensive cancer center.	0
5	Prediction ofBRCA1andBRCA2mutations by the BODICEA and BRCAPRO models and NCCN criteria in Libyan breast cancer women.	0
4	Variability Among Breast Cancer Risk Classification Models When Applied at the Level of the Individual Woman.	0
3	Variant-specific Mendelian Risk Prediction Model.	0
2	Breast cancer genetics and risk assessment: an overview for the clinician. 1-6	0
1	Bilateral risk-reducing mastectomy and reconstruction: A 12-year review of methodological trends and outcomes at a tertiary referral centre. **2023**, 18, e0281601	0